Dutch medtech startup Hy2Care raises €3.7M for hydrogel technology to repair cartilage defects in the knee

Dutch medtech startup Hy2Care raises €3.7M for hydrogel technology to repair cartilage defects in the knee

This article will take you 2 minute(s) to read

Hy2Care BV, an innovative startup company that developed a groundbreaking hydrogel technology for cartilage repair, has raised €3.7 million in funding. The series A round was led by Brightlands Venture Partners and assisted by several co-investors and the Dutch Arthritis Society (ReumaNederland, previously Reumafonds). With the funding, the spin-off of the University of Twente will further commercialize the technology for veterinary use as well as initiate human trials.

Founded in 2014, Hy2Care focuses on the development and commercialisation of a new hydrogel device that has shown impressive results in repairing cartilage defects. Previously typified as an ‘injectable plaster’, the hydrogel technology enables a fast repair of acute cartilage defects that often occur as a result of falls, accidents and sports injuries. The procedure promises a great improvement in near-term functionality and pain relief compared to current methods like arthroscopic debridement and microfracturing. Moreover, the hydrogel can be used during the initial arthroscopic viewing procedure, thereby diminishing the need for secondary surgery and revalidation.

Groundbreaking Research

The unique technology of Hy2Care was developed by prof. Marcel Karperien and his team of the Developmental BioEngineering group at the University of Twente. The latter will remain a shareholder in Hy2Care through its entrepreneurship accelerator, Novel-T. Prof Karperien will continue fulfilling the role of Chief Scientific Officer.

“There is a major unmet need for repairing traumatic cartilage defects,” says Marcel Karperien. “If not treated well, about 80% of these defects will lead to arthrosis, ultimately causing severe pain and needing very invasive solutions like artificial knee replacements. By coming up with a better early repair, we prevent much discomfort for patients as well as reduce significant healthcare costs”.

Major Commitments

“Having observed with Key Opinion Leaders the very promising results of the early preclinical tests, Hy2Care may be well on track to generate a breakthrough solution for acute cartilage defects in knees and other joints. As such, it is a great addition to our portfolio, in which we actively seek out companies pursuing unique solutions in healthcare”, according to Marcel Kloosterman, Director at Brightlands Venture Partners, who led the investment round. ReumaNederland, previously Reumafonds is also an active supporter.

They recently presented the Developmental BioEngineering group at the University of Twente with the “Research Center of Excellence” status in the field of arthrosis and intend to continue their support in the upcoming years to enable the technology to be proven clinically and successfully reaching patients.

Stay tuned to Silicon Canals for more updates in the tech startup world.

Build a career in emerging tech: 5 things you need to know about EIT Digital Academy Summer Schools 2019

Leave a Reply

*